Pavlina Suchanova, MD
Otolaryngology · Sugar Land, TXNPI 1750603700
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Optinose US, Inc. at 50.5% of the total. 2025 is the largest year on record at $34,494, more than ten times the $3,171 reported in 2019. Among otolaryngology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 324 payments — averaging $208.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$34K
- Aerin Medical Inc.$23K
- Stryker$4K
- Intersect ENT, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$782
- Sanofi$728
- plus $3K from 20 others
What the payments were for
- Consulting fees$16,57924%
- Speaking & faculty fees$29,42543%
- Travel & lodging$4,5597%
- Food & beverage$17,13425%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 87 | $34,155 |
| Aerin Medical Inc. | 46 | $22,568 |
| Stryker | 47 | $4,251 |
| Intersect ENT, Inc. | 21 | $2,543 |
| Regeneron Healthcare Solutions, Inc. | 25 | $782 |
| Sanofi | 19 | $728 |
| Medtronic(2 entities) | 12 | $592 |
| GSK | 20 | $504 |
| Acclarent, Inc | 2 | $264 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $223 |
| Hikma Pharmaceuticals USA | 8 | $180 |
| Grifols USA, LLC | 4 | $169 |
| Alk-abello, Inc | 5 | $169 |
| Arrinex, Inc. | 1 | $131 |
| CSL Behring | 4 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| Paratek Pharmaceuticals, Inc. | 2 | $50 |
| Octapharma USA, Inc. | 1 | $49 |
| Inspire Medical Systems, Inc. | 2 | $40 |
| Kaleo, Inc. | 2 | $39 |
| Novartis | 2 | $28 |
| Amgen | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Olympus America Inc. | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xhance$33,009
- VIVAER STYLUS$21,081
- RHINAER STYLUS$2,244
- PROPEL$1,518
- XPRESS ENT DILATION SYSTEM$1,185
- ENTELLUS - XPRESS ENT DILATION SYSTEM$1,124
- SINUVA$1,068
- SCOPIS ENT$651
- Vivaer RF Stylus$558
- DUPIXENT$358
- LATERA$343
- AUDION ET DILATION SYSTEM$339
- ENTELLUS - FIAGON SINUS NAVIGATION SYSTEM$232
- NUCALA$187
- TruDi Nav Cable$135
- SPIROX - LATERA$134
- CLARIFIX$131
- ACCLARENT ENT ULTIRRA/NAVWIRE 3-GUIDE Bundle$129
- NUVENT$128
- Xembify$125
How this compares
$67,697 in reported general payments places this provider in the 95th percentile of 729 otolaryngology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XhanceFluticasone Propionate | 41 | $31,299 |
| RyaltrisOlopatadine Hcl/Mometasone | 52 | $13,644 |
| Budesonide | 67 | $6,836 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 26 | $3,293 |
| Dexlansoprazole DrDexlansoprazole | 11 | $2,127 |
| Doxycycline Hyclate | 137 | $1,610 |
| Omeprazole | 167 | $1,422 |
| Ipratropium Bromide | 49 | $987 |
| Methylprednisolone | 133 | $866 |
| Azelastine Hcl | 32 | $811 |
| Fluticasone Propionate | 34 | $423 |
| Famotidine | 51 | $334 |
| Mupirocin | 44 | $284 |
| Levofloxacin | 30 | $145 |
| Ciprofloxacin Hcl | 18 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $34,155 | $31,29941 claims |
| Hikma Pharmaceuticals USARyaltris | $180 | $13,64452 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 otolaryngology providers in Texas.
Other otolaryngology in Sugar Land
- Marc DeanFort Worth$486K
- Amber LuongHouston$426K
- Arjuna KuperanHouston$348K
- Ronald KuppersmithCollege Station$325K
- Ron KarniHouston$317K
- Philip ChenSan Antonio$305K
- Jordan RihaniSouthlake$280K
- Keith MathenyFrisco$269K
- Martin CitardiHouston$245K
- James AtkinsSan Antonio$205K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.